This overview of the 2025 European Association of Urology guidelines offers valuable insights into the risk factors, diagnosis, classification, treatment, and follow-up of muscle-invasive bladder canc...

Zanidatamab plus palbociclib and fulvestrant was generally safe and showed promising antitumour activity, supporting further evaluation of this chemotherapy-free triplet regimen.

Advances in cancer biology and drug development now enable treatments tailored to individual tumor profile. Targeting specific molecular alterations, marking a significant step forward in cancer care,...

Purpose Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant e...

Galsky and colleagues report the results of a phase 1 clinical trial of anti-programmed cell death protein 1 ligand 1 atezolizumab in combination with PGV001, a personalized neoantigen vaccine, in par...

Prostate Cancer and Prostatic Diseases - Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II...

PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth f...

PURPOSECyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor–positive/human epidermal growth f...

Clinical prediction models are increasingly used to guide treatment in patients with early breast cancer. The Danish Breast Cancer Group (DBCG) has de…

Despite its radioresistant reputation, renal cell carcinoma (RCC) is sensitive to high dose per fraction stereotactic ablative body radiotherapy (SABR…

Leptomeningeal metastases (LM) in patients with breast cancer (BC) are associated with a dismal prognosis. We explored clinical characteristics and prognostic factors in patients with BC and LM in the...

This nonrandomized trial examines 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients with breast cancer selected with image-guided vacuum assisted biopsy.

This study analyzed the correlation of invasive disease-free survival (iDFS) and overall survival (OS) in the adjuvant HR+/HER2– early breast cancer (EBC) setting using real-world patient data. The r....

This cohort study of US adults with metastatic clear cell renal cell carcinoma examines changes in forms of treatment used following the approval of immune-checkpoint inhibitor combinations by the US ...

Immune checkpoint inhibitors (ICI) have been investigated in combination with preoperative chemotherapy in early-stage triple negative breast cancer (TNBC) and in estrogen receptor-positive, human epi...

The treatment landscape for patients with advanced urothelial carcinoma (UC) has evolved rapidly in recent years. In current guidelines, combination t…

Angioscore is a transcriptome based predicter of treatment response in clear cell renal cell carcinoma. Here, the authors use deep learning to infer the Angioscore from histopathology slides using cli...

Background Triple-negative breast cancer (TNBC) patients are at increased risk for recurrence compared to other subtypes of breast cancer. Previous evidence showed that adiposity may contribute to wor...

PURPOSEThe COSMIC-021 study assessed the safety and efficacy of cabozantinib plus atezolizumab in advanced solid tumors. Presented here are results from the expansion cohorts with advanced urothelial ...

PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherap...

Management of advanced non-clear cell renal cell carcinoma (nccRCC) is challenging due to disease rarity and heterogeneity. The combination of multi-targeted tyrosine kinase inhibitor (TKI) with im...

PURPOSETo assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for earl...

This cohort study examines interruption and resumption of endocrine therapy among women with breast cancer who became pregnant.

Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may be associated with aggressive disease and poorer outcomes, and can have hereditary cancer implications fo...

Purpose Adding CDK4/6 inhibitors (CDK4/6is) to endocrine therapy (ET) for HR+/HER2− early breast cancer (EBC) demonstrated statistically significant invasive disease-free survival (iDFS) benefits in m...

Purpose Advances in contemporary breast cancer care (e.g., early detection, increased use of preoperative chemotherapy, and updated SSO–ASTRO margin guidelines) have the collective potential to influe...

PURPOSEAfter radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherap...

For inoperable patients, stereotactic body radiation therapy (SBRT) is a noninvasive treatment approach for primary renal cell carcinoma (RCC). We aim…

Purpose Glucocorticoid receptor (GR) activity may mediate chemoresistance in advanced triple-negative breast cancer (TNBC). Preclinical studies demonstrate that GR antagonism can augment the effect of...

AbstractBackground. This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma

Objectives To assess the contemporary malignancy rate in isolated de novo red patches in the bladder and associated risk factors for better selection of red patch biopsy. Patients Patients from th...

For patients aged 50 years or older and at 3 years post diagnosis, less frequent mammograms were non-inferior compared with annual mammograms for breast cancer-specific survival, recurrence-free inter...